Neurotech Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Neurotech Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Neurotech Pharmaceuticals: 13 sponsored US clinical trials, 1 recruiting.
Neurotech Pharmaceuticals sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 10 completed. 4 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Macular Telangiectasia Type 2 (MacTel), with 1 trials.
Top-decile sponsor footprint
Neurotech Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
13 total, page 1 of 1
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
NCT06971939
A Study to Determine the Safety and Efficacy of NT-501 With MHFM
NCT06397131
Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2
NCT04729972
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
NCT03319849
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A
NCT03316300
Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)
NCT03071965
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
NCT02228304
A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel
NCT01949324
Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01530659
Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)
NCT01327911
A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447980
A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT00447993
A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration
NCT00447954
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 7 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Neurotech Pharmaceuticals pipeline
1 recruiting of 13 indexed (8% open); 10 completed (77%).
Phase mix: 4 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top condition: Macular Telangiectasia Type 2 (MacTel) (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Neurotech Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Neurotech Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
- Fresenius Medical Care North America · 8% recruiting · 13 trials
Related
What to do with this Neurotech Pharmaceuticals page
13 registered trials is a research-attention snapshot, not an endorsement of Neurotech Pharmaceuticals or any single study.
- 1 of Neurotech Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Macular Telangiectasia Type 2 (MacTel) is the condition Neurotech Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Macular Telangiectasia Type 2 (MacTel) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Neurotech Pharmaceuticals pipeline card: 13 registered trials from official public datasets.Report a data error.